NCT06332573 Impact of Onco-sexology Support on the Quality of Life of Patients Newly Diagnosed for Cancer
| NCT ID | NCT06332573 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hôpital Européen Marseille |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 168 participants |
| Start Date | 2025-04-22 |
| Primary Completion | 2027-08-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 168 participants in total. It began in 2025-04-22 with a primary completion date of 2027-08-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Onco-sexology as a supportive care for patients treated for cancer is still rarely discussed or even non-existent in 2022. However, it's recommended to integrate the preservation of sexual health throughout the treatment and post-cancer process, given the impact of cancer, treatments and the importance of intimate life for a majority of patients. Onco-sexology is one of the supportive care services validated by The French National Cancer Institute (INCa). It is also an objective of the 2014-2019 cancer plan and the 2017-2030 national sexual health strategy plan. Although sexuality is one of the fundamental needs of the human being, including in the case of a chronic disease or cancer diagnosis, the lack of training of health professionals to deal with intimate life, the difficulty to exchange on this subject between caregivers and patients, the lack of financial support for onco-sexology consultations, are all obstacles to the global management of oncology patients. However, it's a request from patients to be able to discuss the subject in an intimate way with a professional. While onco-sexology is already recommended as supportive care, a study on the impact of the delay in the management of sexual difficulties on quality of life could provide a sufficient level of evidence to change the practices and the care pathway of the oncology patient. Our objective is to study whether early management in onco-sexology has an impact on quality of life compared to late management (ie onco-sexology consultation before vs. after introduction of systemic oncological treatment).
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 18 years * Newly cancer diagnosis, including palliative care * Having given free and informed written consent Exclusion Criteria: * Pregnant or breastfeeding woman * Persons deprived of their liberty by a judicial or administrative decision. * Persons who are subject to a legal protection measure or who are unable to express their consent.
Frequently Asked Questions
Who can join the NCT06332573 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06332573 currently recruiting?
Yes, NCT06332573 is actively recruiting participants. Visit ClinicalTrials.gov or contact Hôpital Européen Marseille to inquire about joining.
Where is the NCT06332573 trial being conducted?
This trial is being conducted at Marseille, France.
Who is sponsoring the NCT06332573 clinical trial?
NCT06332573 is sponsored by Hôpital Européen Marseille. The trial plans to enroll 168 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.